Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Progyny, Inc. (PGNY) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission documents, along with AI-powered summaries to help interpret the information. Progyny’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Global Select Market, so its filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, among others.
For a benefits management company in the healthcare plans sector, annual reports (Form 10-K) and quarterly reports (Form 10-Q) are key sources for understanding revenue from fertility benefit services and pharmacy benefit services, client and member metrics, risk factors, and management’s discussion of operations. AI summaries can highlight how Progyny describes its women’s health and family building solutions, its clinical networks, and the factors that influence utilization and margins.
Current reports on Form 8-K document material events such as quarterly earnings releases, the entry into a revolving credit facility, and executive leadership changes. For example, recent 8-K filings reference financial results for specific quarters, the establishment of a $200 million revolving credit facility under a Credit Agreement, and the planned cessation of employment of the company’s president along with a consulting arrangement. AI analysis can surface the sections that describe these events, summarize their implications, and point to related exhibits.
Investors and analysts interested in executive arrangements, capital structure, and financing can use this page to review disclosures about the revolving credit facility, guarantees by subsidiaries, and covenants such as leverage and interest coverage ratios, as described in the July 1, 2025 Form 8-K. Over time, filings also provide context on stock repurchase authorizations, share-based compensation, and other capital priorities.
The filings page also makes it easier to monitor risk disclosures and regulatory language. Progyny’s safe harbor statements and risk factor summaries discuss competition, client retention, utilization variability, regulatory changes, data security, relationships with providers and pharmacy partners, and other issues that can affect results. With real-time updates from EDGAR and AI-generated explanations, users can quickly locate the most relevant sections of long documents, whether they are reviewing a 10-K, a 10-Q, or a Form 4 related to insider transactions.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported new equity awards. She received a grant of stock options for 66,289 shares of common stock at no exercise cost in this report, recorded as a derivative security.
She also received 45,454 shares of common stock in the form of restricted stock units under Progyny’s 2019 Equity Incentive Plan. For each grant, 33% vests on the first anniversary of the March 2 grant date, with the remaining portion vesting in quarterly installments through the third anniversary, as long as she continues in service.
Progyny, Inc. EVP and General Counsel Allison Swartz reported multiple equity transactions in Progyny (PGNY) stock. On March 2, 2026, she received an annual merit grant of 28,409 shares of common stock and 41,430 stock options under the 2019 Equity Incentive Plan. These awards vest 33% on the first anniversary of the grant date, with the remainder vesting quarterly through the third anniversary, contingent on continued service. That same day, 1,551 shares were withheld at $17.69 per share to cover taxes on RSU vesting, and 2,199 shares were sold at $17.27 per share under a Rule 10b5-1 trading plan. On March 3, 2026, an additional 2,842 shares were withheld for taxes at $17.60 per share, and 500 shares and 4,157 shares were sold at $17.396 and $17.40 per share, respectively, also under the 10b5-1 plan. Following these transactions, she held 89,879 shares of common stock directly.
Progyny, Inc.’s chief financial officer Mark S. Livingston reported a mix of equity grants and related tax withholdings. He received a grant of 45,454 shares of common stock as restricted stock units and a separate stock option for 66,289 shares, both as annual merit awards under the 2019 Equity Incentive Plan. In connection with RSU vesting, the company withheld 4,579 shares on one date and 181 shares on another date at prices around $17.60–$17.69 per share to cover tax obligations, leaving him with 87,677 common shares directly owned after the larger withholding transaction.
Progyny, Inc. CEO Peter Anevski reported equity compensation and related tax withholding transactions. On March 2, 2026, he was granted 159,091 shares of common stock as restricted stock units and 232,011 stock options, both as annual merit grants under Progyny’s 2019 Equity Incentive Plan.
These awards vest over three years, with 33% vesting after one year and the remainder vesting quarterly, subject to continued service. On March 3, 2026, 17,611 common shares were withheld to cover taxes upon RSU vesting, leaving 816,833 common shares held directly. An additional 1 share is held indirectly through PECO ANEVSKI 2020 SD LLC.
PGNY Form 144 notice lists proposed dispositions of common stock by Allison C. Swartz and a 599-share restricted stock vesting to Fidelity Brokerage Services LLC. The excerpt shows three sales by Allison C. Swartz: 12/04/2025 ($13,032.70, 530 shares), 03/02/2026 ($37,976.73, 2,199 shares) and 03/03/2026 ($81,029.55, 4,657 shares). It also lists 599 shares from a restricted stock vesting on 03/04/2026 associated with Fidelity Brokerage Services LLC and labeled Compensation.
Allison C. Swartz reported proposed and recent dispositions of PGNY common stock. The filing lists 4,657 shares to be sold in connection with restricted stock vesting on 03/03/2026. It also shows prior sales of 530 shares on 12/04/2025 (for $13,032.70) and 2,199 shares on 03/02/2026 (for $37,976.73).
Brokerage details name Fidelity Brokerage Services LLC as the broker of record and the securities are listed on NASDAQ.
Allison C. Swartz submitted a Form 144 notice reporting proposed transactions in common stock tied to restricted stock vesting as compensation. The filing lists 2,199 shares in the securities table and records a prior sale of 530 shares on 12/04/2025.
Progyny, Inc. files its annual report describing a fast‑growing women’s health and family building benefits platform. The company serves more than 590 self‑insured employers across over 40 industries, covering about 7.2 million employees and dependents through fertility, pharmacy, pregnancy, menopause and family support solutions.
Progyny highlights its proprietary Smart Cycle plan design, integrated Progyny Rx pharmacy benefit, selective Center of Excellence fertility network and concierge care advocates, which it says drive higher live birth rates and fewer multiple births than national averages. The filing also outlines extensive regulatory, competitive, macroeconomic, data privacy and technology (including AI) risks that could affect future growth and profitability.
Progyny, Inc. reported record 2025 results and raised its outlook for 2026. Full-year 2025 revenue reached $1,288.7 million, up 10% from 2024, or 20% excluding a large former client under a transition agreement. Gross profit rose 20% to $304.5 million, lifting gross margin to 23.6%.
Net income for 2025 was $58.5 million, or $0.65 per diluted share, with Adjusted EBITDA of $222.1 million and a 17.2% Adjusted EBITDA margin. Operating cash flow hit a record $210.2 million. As of December 31, 2025, Progyny had $310.1 million in cash and marketable securities, $349.4 million of working capital, and no debt.
In the fourth quarter, revenue was $318.4 million, up 6.7% year over year, or 21% excluding the former client, while gross margin expanded to 24.1%. The company repurchased 3.3 million shares for $83.6 million in the quarter and about 6.5 million shares to date, spending roughly $160 million under its $200 million authorization.
For 2026, Progyny projects revenue of $1.355 billion to $1.405 billion, net income of $95.4 million to $106.1 million (or $1.10 to $1.22 per diluted share), Adjusted EBITDA of $224.0 million to $239.0 million, and continued revenue growth excluding the transitioned client.
Progyny, Inc. furnished an update to its previously issued financial guidance for the three months and full year ending December 31, 2025. The company did this by issuing a press release dated January 12, 2026, which is attached as Exhibit 99.1 to this Form 8-K and incorporated by reference into the disclosure under Item 2.02. The information in this item and the exhibit is being furnished rather than filed under securities laws, meaning it is not subject to certain liability provisions and is not automatically incorporated into other regulatory documents.